Cricket Health company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

crickethealth.com

Founded Year

2015

Stage

Merger | Merged

Total Raised

$127.75M

About Cricket Health

Cricket Health is a comprehensive kidney care provider with a personalized, evidence-based approach to managing CKD and ESRD. Through a combination of software and services, the company makes home dialysis accessible to a larger pool of patients and improves medical outcomes for these patients.On March 22nd, 2022, Cricket Health merged with Transforming Kidney Care.

Cricket Health Headquarter Location

251 Kearny St. Floor 7

San Francisco, California, 94108,

United States

888-780-0253

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cricket Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cricket Health is included in 4 Expert Collections, including Digital Health 150.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

V

Value-Based Care & Population Health

873 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

D

Digital Health

12,999 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

T

Telehealth

2,832 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Latest Cricket Health News

Renibus Therapeutics Expands Leadership Team, Announces Appointments of New Chief Financial Officer and Chief Medical Officer

Jun 2, 2022

Jamie Donadio appointed Chief Financial Officer and Bhupinder Singh, MD, appointed Chief Medical Officer Appointments bring more than 40 combined years of proven leadership, clinical and commercial experience to the company Appointments support rapid acceleration of Renibus’ clinical portfolio SOUTHLAKE, Texas, June 02, 2022 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced the expansion of its leadership team with the appointment of Jamie Donadio as Chief Financial Officer, and Bhupinder Singh, MD, as Chief Medical Officer. Both Mr. Donadio and Dr. Singh will report to Renibus’ Chairman and Chief Executive Officer (CEO), Frank Stonebanks. The addition of these seasoned biotech leaders comes at a critical time, as Renibus continues to scale and develop its portfolio of products that aim to transform both the prevention and treatment of kidney disease. “I am excited to welcome Jamie and Bhupinder to Renibus’ executive team as we look to accelerate our efforts and prepare for upcoming clinical, financial and business milestones this year,” said Stonebanks. “Renibus will benefit from their collective financial and clinical expertise, tenured leadership and strategic insights as we look to transform the cardio-renal disease treatment paradigm.” Jamie Donadio brings more than 20 years of finance and accounting experience at both public and private biotech and pharmaceutical companies. He will oversee Renibus’ finance organization as the company enters a critical phase of growth and executes its clinical development strategy for lead products RBT-1, RBT-2 and RBT-3. Jamie is a seasoned biotech CFO, experienced in helping companies scale during periods of rapid growth, and brings significant experience executing public and private financing transactions. Mr. Donadio most recently served as CFO at BioTheryX, Inc., senior vice president, chief financial officer at Mirati Therapeutics and senior director of finance at Amylin Pharmaceuticals. Prior to Amylin, Jamie held finance and auditing roles at Novatel Wireless and Ernst & Young. He holds a Bachelor of Science in Accounting from Babson College. “I am thrilled to join the Renibus management team and support the continued development of the company as it seeks to create innovative solutions to prevent and treat kidney diseases,” said Donadio. Dr. Bhupinder Singh is a leading nephrologist, biotech board member and clinical advisor, and clinical professor in the Division of Nephrology at the University of California, Irvine School of Medicine. He brings more than 20 years of experience across biotech clinical development, medical affairs and clinical practice. Dr. Singh was a founder of the Southwest Kidney Institute, where he served as a member of the executive board and led various clinical and research programs. While in practice and thereafter at ZS Pharma, he led the clinical development of LOKELMA®, which is now approved for the treatment of hyperkalemia. His research work has been published in prominent medical journals including the New England Journal of Medicine, JAMA, Kidney International and CJASN. As Chief Medical Officer, he will lead the clinical development efforts of Renibus’ pipeline, including the ongoing Phase 2 study of RBT-1, the Phase 1/2 study of RBT-2 and the Phase 3 study of RBT-3. Dr. Singh received his medical degree from the Armed Forces Medical College, a leading medical institute in India. He is a clinical advisor to Cricket Health and a member of Renibus’ Board of Directors. “I am excited to join Renibus Therapeutics as Chief Medical Officer as we look to address critically important unmet patient needs and drive innovation in kidney care,” said Dr. Singh. “I look forward to leading Renibus’ clinical development and medical affairs teams to develop and bring to market our pipeline of promising cardio-renal clinical products.” About Renibus Therapeutics, Inc. Renibus Therapeutics is a clinical-stage biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention and treatment of kidney disease. The company’s portfolio includes RBT-1 for prevention of hospital-acquired acute kidney injury (HA-AKI), RBT-2 for treatment of chronic kidney disease, and RBT-3 for prevention of cisplatin-induced nephrotoxicity. For more information, please visit the Company’s website at www.Renibus.com . Media Contact

Cricket Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cricket Health Rank

  • When was Cricket Health founded?

    Cricket Health was founded in 2015.

  • Where is Cricket Health's headquarters?

    Cricket Health's headquarters is located at 251 Kearny St., San Francisco.

  • What is Cricket Health's latest funding round?

    Cricket Health's latest funding round is Merger.

  • How much did Cricket Health raise?

    Cricket Health raised a total of $127.75M.

  • Who are the investors of Cricket Health?

    Investors of Cricket Health include Transforming Kidney Care, K2 HealthVentures, Oak HC/FT Partners, Blue Shield of California, Valtruis and 15 more.

  • Who are Cricket Health's competitors?

    Competitors of Cricket Health include Somatus and 7 more.

You May Also Like

S
Somatus

Somatus aims to delay or prevent the progression of chronic kidney disease (CKD) to ESRD, help eligible patients access home-based dialysis modalities which improve their outcomes, and maximize the number of patients who qualify for and receive kidney transplantation. Users can receive concierge kidney care in the comfort of your home. As a patient, they will have direct access to 24/7 medical attention. Somatus' team will be comprised of nurses, physicians, and other health professionals who can anticipate as well as address medical needs.

M
Monogram Health

Monogram Health has developed an artificial intelligence algorithm to predict necessary and timely care to promote the delay of Kidney Disease progression, and an easy transition to dialysis and/or pre-emptive kidney transplant, as well as to optimize patient health outcomes once on dialysis.

Strive Health Logo
Strive Health

Strive Health delivers a kidney care service line for health systems and payors, powered by specialized analytics and Nephrology caregivers.

Healium Digital Healthcare Logo
Healium Digital Healthcare

Healium Digital Healthcare is a healthcare AI company focused on early detection and management of high burden diseases like chronic kidney disease through non-invasive digital biomarkers.

IKONA Health Logo
IKONA Health

IKONA offers a smarter way for kidney care providers to deliver effective and measurable learning experiences to their patients and staff. Its platform uses learning science and storytelling to address education and training challenges, dramatically improve patient understanding and ensure smarter, confident treatment decisions.

Renaltracker Logo
Renaltracker

RenalTracker is a web/mobile behaviour-changing platform for Chronic Kidney Disease (CKD) empowering patients through personalised, coach-guided wellness in-between doctor's visits.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.